CTLA4 and neoplasm: Perhaps the tumor reactivity we appreciated, measured by total number of specificities and sum est freq, is enriched with anti-CTLA-4 treatment because more tumor reactive TILs will receive the costimulation needed in the priming phase to become activated and localize to the tumor, thus boosting the T cell repertoire we found in these samples.